izpis_h1_title_alt

MHC class II molecules and tumour immunotherapy
Oven, Irena (Author)

URLURL - Presentation file, Visit http://www.dlib.si/details/URN:NBN:SI:doc-9ZAYHU9A This link opens in a new window

Abstract
Tumour immunontherapy attempts to use the specificity and capability of the immune system to kill malignant cells with a minimum damage to normal tissue. Increasing knowledge of the identity of tumour antigens should help us design more effective therapeutic vaccines. Increasing evidence has demonstrated that MHC class II molecules and CD4+T cells play important roles in generating and maintaining antitumour immune responses in animal models. These data suggest that be necessary to involve both CD+ and CD+T cells for more effective antitumour therapy. Novel strategies have been developed for enhancing T cell responses against cancer by prolonging antigen prersentation of denritic cells to T cells, by the inclusion of MHC class II-restricted tumour antigens and by genetically modifying tumour cells to present antigen to T lymphocytes directly. Vaccines against cancers aim to induce tumour-specific effector T cells that can reduce tumour mass and induce development of tumour-specific T cell memory, that can control tumour relapse.

Language:English
Keywords:klinična medicina, rak, onkologija, tumorji, imunoterapija
Work type:Not categorized (r6)
Tipology:1.02 - Review Article
Organization:BF - Biotechnical Faculty
Year:2005
Publisher:Croatian Medical Association - Croatian Society of Radiology
Number of pages:str. 261-268
Numbering:Letn. 39, št. 4
UDC:616-006
ISSN on article:1318-2099
COBISS.SI-ID:1837704 Link is opened in a new window
Views:560
Downloads:121
Metadata:XML RDF-CHPDL DC-XML DC-RDF
 
Average score:(0 votes)
Your score:Voting is allowed only to logged in users.
:
Share:AddThis
AddThis uses cookies that require your consent. Edit consent...

Record is a part of a journal

Title:Radiology and oncology
Shortened title:Radiol Oncol
Publisher:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 This link opens in a new window

Secondary language

Language:English
Title:[Pomen molekul MHC pri imunoterapiji tumorjev]
Abstract:
Izhodišča. Imunoterapija tumorjev izrablja sposobnost imunskega sistema, da se specifično ubija tumorske celice, pri tem pa minimalno poškoduje normalno tkivo. Vedno večje poznavanje tumorskih celic, pri tem pa minimalno poškoduje normalno tkivo. Vedno večje poznavanje tumorskih antigenov prispeva k načrtovanju bolj učinkovitih terapevtskih cepiv. Študije narejene na živalskih modelih so pokazale, da so poleg molekul MHC I in celic CD8+ T pri nastanku in vzdrževanju imunskega odziva proti tumorjem pomembne tudi molekuleMHC II in celice CD4+ T. Rezultati nakazujejo, da bo za učinkovito protitumorsko cepivo potrebno aktivirati tako celice CD4+ kot tudi CD8+ T. V zadnjem času so se razvile nove strategije za okrepitev T celičnega odgovora proti raku, ki izrabljajo sposobnost dendritiènih celic, da delujejo kot antigeni. Z vključevanjem tumorskih antigenov specifičnih za molekule MHC II in z genetičnim spreminjanem tumorskih celic, da delujejo kot antigeni (antigen-predstavitvene celice), lahko podaljšamo predstavljanje antigenov celicam T preko dendritičnih celic. Zaključki. Z združitvijo različnih pristopov bi lahko naredili učinkovito protitumorsko cepivo, ki bi vzpodbudilo delovanje za tumor specifičnih celic T, te pa bi ubile tumorske celice. S tem bi zmanjšale obseg tumorja, obenem pa bi vzpodbudile tudi nastanek za tumor specifičnega celičnega spomina T, ki bi omejil ali preprečil ponovni nastanek tumorja.


Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Comments

Leave comment

You have to log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back